Q93.52
Phelan-McDermid syndrome
Clinical Classification Guidelines
Use Additional Code
- code(s) to identify any associated conditions, such as:
- autism spectrum disorder (F84.0)
- degree of intellectual disabilities (F70-F79)
- epilepsy and recurrent seizures (G40.-)
- lymphedema (I89.0)
Inclusion Terms
- 22q13.3 deletion syndrome
Medical Intelligence & Overview
Phelan-McDermid syndrome, classified under ICD-10 code Q93.52, is a rare genetic disorder caused by deletions or mutations in the 22q13.3 region of chromosome 22. This condition is characterized by developmental delays, intellectual disabilities, and distinct physical features. Also referred to as 22q13.3 deletion syndrome, it affects multiple systems in the body and can vary significantly in severity from one individual to another. Early diagnosis and supportive care can help manage many of the symptoms associated with this syndrome.
Causes & Symptoms
Clinical Causes: Deletion of a segment at the end of the long arm (q) of chromosome 22, specifically at band 13.3. Mutations or disruptions in the SHANK3 gene, which plays a critical role in brain development and synaptic function. In most cases, the syndrome occurs due to a spontaneous genetic mutation during reproductive cell formation, with some cases inherited from a parent carrying a balanced chromosomal rearrangement.
Key Symptoms: Developmental delays, including delays in speech and motor skills. Intellectual disabilities. Absent or severely delayed speech development. Low muscle tone (hypotonia). Distinctive physical features such as a small head (microcephaly), pointed chin, and long face. Calm and withdrawn behavior, sometimes with autistic features. Delays in walking and other motor skills. Problems with feeding in infancy, such as difficulty swallowing or poor sucking reflex. Seizures in some individuals. Gastrointestinal issues, including constipation or feeding difficulties. Sensitivity to stimuli and potential behavioral challenges.
Diagnostic & Treatment
Diagnosis Path: Diagnosis typically involves a detailed clinical evaluation, including assessment of physical features and developmental milestones. Confirmatory testing is performed using genetic techniques such as fluorescence in situ hybridization (FISH), microarray analysis, or targeted gene testing to identify deletions or mutations in chromosome 22q13.3. Early genetic testing is essential for distinguishing this syndrome from other developmental disorders and for planning appropriate interventions.
Treatment Protocols: There is no cure for Phelan-McDermid syndrome; treatment focuses on managing symptoms and supporting development. Multidisciplinary approaches may include: - Speech and language therapy to improve communication skills. - Physical and occupational therapy to enhance motor skills and daily functioning. - Educational interventions tailored to the child's learning needs. - Behavioral therapies to address behavioral challenges and foster social skills. - Medical management for seizures or gastrointestinal issues. - Regular health evaluations to monitor and address emerging health concerns. Support from healthcare professionals, educators, and family members is vital in optimizing quality of life for individuals with this condition.
Clinical Advice & FAQs
Billing Guidance
Is Q93.52 a billable ICD-10 code?
Yes, Q93.52 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Q93.52?
Clinical documentation must specify the nature of Phelan-McDermid syndrome and any associated comorbidities for accurate reporting.
Cite this Clinical Reference